Table 1 Distribution of patients between treatment sequences
From: Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
Sequence | Allocation ratio | Treatments | Delivery device | ||
|---|---|---|---|---|---|
Period 1 | Period 2 | Period 3 | |||
1 | 7 | Placebo | FF 200 μg OD | FF 100 μg BD | Novel dry powder inhaler |
2 | 7 | Placebo | FF 100 μg BD | FF 200 μg OD | |
3 | 7 | FF 100 μg BD | Placebo | FF 200 μg OD | |
4 | 7 | FF 100 μg BD | FF 200 μg OD | Placebo | |
5 | 7 | FF 200 μg OD | Placebo | FF 100 μg BD | |
6 | 7 | FF 200 μg OD | FF 100 μg BD | Placebo | |
7 | 2 | Placebo | FP 200 μg OD | FP 100 μg BD | Diskus™ inhaler |
8 | 2 | Placebo | FP 100 μg BD | FP 200 μg OD | |
9 | 2 | FP 100 μg BD | Placebo | FP 200 μg OD | |
10 | 2 | FP 100 μg BD | FP 200 μg OD | Placebo | |
11 | 2 | FP 200 μg OD | Placebo | FP 100 μg BD | |
12 | 2 | FP 200 μg OD | FP 100 μg BD | Placebo | |